• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:中亚地区首例确诊的两例法布里病病例

Case Report: First Two Identified Cases of Fabry Disease in Central Asia.

作者信息

Cainelli Francesca, Argandykov Dias, Kaldarbekov Dauren, Mukarov Murat, Tran Thi Phuong Liên, Germain Dominique P

机构信息

Raffles Medical Group Clinic, Phnom Penh, Cambodia.

Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia.

出版信息

Front Genet. 2021 Apr 27;12:657824. doi: 10.3389/fgene.2021.657824. eCollection 2021.

DOI:10.3389/fgene.2021.657824
PMID:33986771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8110900/
Abstract

Fabry disease (FD, OMIM #301500) is a rare, progressive, X-linked inherited, genetic disease due to the functional deficiency of lysosomal α-galactosidase (α-GAL) that leads to the accumulation of glycosphingolipids (mainly globotriaosylceramide or Gb) and its derivative globotriaosylsphingosine or lyso-Gb. Classic FD is a multisystem disorder which initially presents in childhood with neuropathic pain and dermatological, gastrointestinal, ocular, and cochleo-vestibular manifestations. Over time, end-organ damage such as renal failure, cardiac arrhythmia and early stroke may develop leading to reduced life expectancy in the absence of specific treatment. We describe two Kazakh patients who presented in adulthood with a delayed diagnosis. We conducted also a family screening through cascade genotyping. This is the first description of cases of Fabry disease in Central Asia. An extensive family pedigree enabled the identification of ten additional family members. Patients with rare genetic diseases often experience substantial delays in diagnosis due to their rarity and non-specific symptoms, which can negatively impact their management and delay treatment. FD may be difficult to diagnose because of the non-specificity of its early and later-onset symptoms and its X-linked inheritance. Raising awareness of clinicians is important for earlier diagnosis and optimal outcome of specific therapies.

摘要

法布里病(FD,OMIM #301500)是一种罕见的、进行性的、X连锁遗传性疾病,由于溶酶体α-半乳糖苷酶(α-GAL)功能缺陷,导致糖鞘脂(主要是三己糖神经酰胺或Gb)及其衍生物三己糖神经鞘氨醇或溶酶体-Gb蓄积。典型的FD是一种多系统疾病,最初在儿童期表现为神经性疼痛以及皮肤、胃肠道、眼部和耳蜗-前庭症状。随着时间的推移,可能会出现终末器官损害,如肾衰竭、心律失常和早期中风,在没有特异性治疗的情况下会导致预期寿命缩短。我们描述了两名成年后才被延迟诊断的哈萨克族患者。我们还通过级联基因分型进行了家族筛查。这是中亚地区法布里病病例的首次描述。一个广泛的家族谱系使我们能够识别出另外10名家庭成员。患有罕见遗传病的患者往往由于疾病罕见和症状不特异而在诊断上出现显著延迟,这可能会对他们的治疗管理产生负面影响并延误治疗。由于FD早期和晚期症状的非特异性以及X连锁遗传,其可能难以诊断。提高临床医生的认识对于早期诊断和特定疗法的最佳疗效至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05aa/8110900/e8d75884ba26/fgene-12-657824-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05aa/8110900/961bd902629c/fgene-12-657824-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05aa/8110900/9d1a4f04a723/fgene-12-657824-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05aa/8110900/e8d75884ba26/fgene-12-657824-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05aa/8110900/961bd902629c/fgene-12-657824-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05aa/8110900/9d1a4f04a723/fgene-12-657824-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05aa/8110900/e8d75884ba26/fgene-12-657824-g0003.jpg

相似文献

1
Case Report: First Two Identified Cases of Fabry Disease in Central Asia.病例报告:中亚地区首例确诊的两例法布里病病例
Front Genet. 2021 Apr 27;12:657824. doi: 10.3389/fgene.2021.657824. eCollection 2021.
2
The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry Disease among At-Risk Family Members of 83 Index Patients.家族筛查在罕见病中的益处:对 83 名先证者的 165 名高危家庭成员进行基因检测,发现 165 例法布雷病新病例。
Genes (Basel). 2022 Sep 9;13(9):1619. doi: 10.3390/genes13091619.
3
Anderson-Fabry disease: a multiorgan disease.安德森-法布里病:一种多系统疾病。
Curr Pharm Des. 2013;19(33):5974-96. doi: 10.2174/13816128113199990352.
4
Globotriaosylsphingosine (Lyso-Gb) as a biomarker for cardiac variant (N215S) Fabry disease.神经酰胺三己糖苷(Lyso-Gb)作为心脏变异型(N215S)法布雷病的生物标志物。
J Inherit Metab Dis. 2018 Mar;41(2):239-247. doi: 10.1007/s10545-017-0127-2. Epub 2018 Jan 2.
5
2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.《2021年法布里病心脏表现的临床特征、诊断及临床管理TSOC专家共识》
Acta Cardiol Sin. 2021 Jul;37(4):337-354. doi: 10.6515/ACS.202107_37(4).20210601A.
6
Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant.溶血型Gb3升高表明R118C GLA突变是一种病理性法布里变异体。
JIMD Rep. 2019;45:95-98. doi: 10.1007/8904_2018_146. Epub 2018 Dec 20.
7
2024 Update of the TSOC Expert Consensus of Fabry Disease.《法布里病TSOC专家共识2024年更新》
Acta Cardiol Sin. 2024 Sep;40(5):544-568. doi: 10.6515/ACS.202409_40(5).20240731A.
8
Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.经典型和迟发型法布里病患者干血斑与血清中溶血型Gb3水平的相关性
Mol Genet Metab. 2017 Aug;121(4):320-324. doi: 10.1016/j.ymgme.2017.06.006. Epub 2017 Jun 17.
9
Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: A family study.家族研究发现与 Fabry 病相关的不确定致病性基因变异 c.352C>T/p.Arg118Cys 导致的肾脏糖鞘脂沉积
Mol Genet Genomic Med. 2019 Nov;7(11):e981. doi: 10.1002/mgg3.981. Epub 2019 Sep 30.
10
Case report: First diagnosis of Fabry disease in North Macedonia in a patient presenting with kidney failure on hemodialysis.病例报告:北马其顿首次诊断出法布里病,患者因肾衰竭接受血液透析治疗。
Front Genet. 2024 Aug 14;15:1415906. doi: 10.3389/fgene.2024.1415906. eCollection 2024.

引用本文的文献

1
Phenotypic Evolution in Fabry Disease: Our Experience in Indian Cohort.法布里病的表型演变:我们在印度队列中的经验
Indian J Clin Biochem. 2025 Apr;40(2):254-262. doi: 10.1007/s12291-023-01176-7. Epub 2024 Jan 10.
2
Fabry disease in South and Central Asia: Is it truly a rare disease or underappreciated?南亚和中亚地区的法布里病:它真的是一种罕见病还是未得到充分认识?
Pak J Med Sci. 2022 Nov-Dec;38(8):2373-2375. doi: 10.12669/pjms.38.8.7064.
3
Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review.隐匿性卒中患者中法布里病的患病率:一项系统评价。

本文引用的文献

1
and Amenability to Migalastat in Fabry Disease.以及法布里病中米加司他的可接受性。
Mol Ther Methods Clin Dev. 2020 Aug 20;19:24-34. doi: 10.1016/j.omtm.2020.08.012. eCollection 2020 Dec 11.
2
Use of a rare disease registry for establishing phenotypic classification of previously unassigned variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup.利用罕见病登记处对先前未分配的变异体进行表型分类:多学科法布里病基因型-表型工作组的共识分类系统。
J Med Genet. 2020 Aug;57(8):542-551. doi: 10.1136/jmedgenet-2019-106467. Epub 2020 Mar 11.
3
Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
Cureus. 2021 Nov 8;13(11):e19358. doi: 10.7759/cureus.19358. eCollection 2021 Nov.
用于评估伴侣蛋白治疗适用性的 Fabry 病突变特异性 Fab 患者衍生细胞模型。
J Med Genet. 2019 Aug;56(8):548-556. doi: 10.1136/jmedgenet-2019-106005. Epub 2019 Apr 22.
4
Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype- phenotype correlations.法布里病的多个表型领域及其在建立基因型-表型相关性中的意义。
Appl Clin Genet. 2019 Mar 5;12:35-50. doi: 10.2147/TACG.S146022. eCollection 2019.
5
Fabry disease in cardiology practice: Literature review and expert point of view.《心脏病学实践中的法布里病:文献综述和专家观点》。
Arch Cardiovasc Dis. 2019 Apr;112(4):278-287. doi: 10.1016/j.acvd.2019.01.002. Epub 2019 Feb 28.
6
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.酶替代疗法对男性法布里病患者临床结局的影响:欧洲专家小组的系统文献综述
Mol Genet Metab Rep. 2019 Feb 6;19:100454. doi: 10.1016/j.ymgmr.2019.100454. eCollection 2019 Jun.
7
The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts.酶替代疗法对法布瑞病女性患者临床结局的影响——欧洲专家小组的系统文献评价。
Mol Genet Metab. 2019 Mar;126(3):224-235. doi: 10.1016/j.ymgme.2018.09.007. Epub 2018 Sep 27.
8
Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study.法布里病男性和女性患者中p.Asn215Ser(p.N215S)GLA突变的表型特征:一项多中心法布里病注册研究。
Mol Genet Genomic Med. 2018 Apr 12;6(4):492-503. doi: 10.1002/mgg3.389.
9
Fabry disease revisited: Management and treatment recommendations for adult patients.重新审视法布里病:成年患者的管理和治疗建议。
Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28.
10
Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.迟发性法布瑞病,心脏损害悄无声息:高发突变的相关经验。
J Am Coll Cardiol. 2016 Dec 13;68(23):2554-2563. doi: 10.1016/j.jacc.2016.09.943.